Why SCYNEXIS, Inc.’s (SCYX) Stock Is Up 670.21%
As of Monday, June 01, SCYNEXIS, Inc.’s SCYX share price has surged by 670.21%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Commentary & Analysis
Why SCYNEXIS, Inc.’s (SCYX) Stock Is Up 624.82%
As of Monday, June 01, SCYNEXIS, Inc.’s SCYX share price has surged by 624.82%, which has investors questioning if this is right time to sell.Michael Rose
Why SCYNEXIS, Inc.’s (SCYX) Stock Is Up 5.32%
As of Wednesday, May 27, SCYNEXIS, Inc.’s SCYX share price has surged by 5.32%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why SCYNEXIS, Inc.’s (SCYX) Stock Is Down 5.65%
As of Tuesday, May 26, SCYNEXIS, Inc.’s SCYX share price has dipped by 5.65%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why SCYNEXIS, Inc.’s (SCYX) Stock Is Down 5.35%
As of Monday, May 18, SCYNEXIS, Inc.’s SCYX share price has dipped by 5.35%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | SCYX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $36.8 | $569.9 | 14% |
|
| Shares Out (Mil) | 6.4 | 44.8 | 16% |
|
| Institutional Ownership | 92.3% | 84.6% | 61% |
|
| Float (Mil) | 7.7 | 45.1 | 16% |
|
| Beta | 1.06 | 0.67 | 63% |
|
| Avg Daily Volume (000s) | 64 | 294 | 31% |
|
| Price Change (52-week) |
(34.6%) | 65.2% | 22% |
|
| Growth | SCYX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 31.1% | (2.0%) | 85% |
|
| EPS (5yr) | 49.3% | 14.9% | 93 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (54.1%) | (14.9%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 2 | 2 | |
| Current EPS | ($0.507) | ($4.080) | ($2.520) | |
| Month Ago EPS | ($0.507) | ($4.080) | ($2.520) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.827) | ($3.360) | ($2.000) | |
| Year/Year Chg | (84.8%) | 195.9% | 14.1% | |
| Financials | SCYX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $20 | $230 | 13% |
|
| Net Income (TTM) (Mil) | ($25) | ($11) | 22% |
|
| EPS (TTM) | ($3.898) | ($0.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($6) | 23% |
|
| Net Cash Flow (TTM) (Mil) | $29 | $4 | 66% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $7 | 19% |
|
| Enterprise Value (Q1) (Mil) | ($19) | $493 | 1% |
|
| Valuation | SCYX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.70 | 2.89 | 14% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SCYX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 65.9% | 96% |
|
| Net Margin | (120.5%) | (0.2%) | 7% |
|
| ROA | (33.7%) | (25.5%) | 16% |
|
| ROE | (53.4%) | (21.4%) | 15% |
|
| Liabilities to Assets | 46.8% | 35.5% | 38% |
|
| F-Score | 2 | 3 | 7% |
|
SCYNEXIS, Inc. did not pass any screens on 7/30/2026.
